M. Mrazova
University of Trnava
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. Mrazova.
Supportive Care in Cancer | 1999
V. Krcmery; M. Mrazova; A. Kunova; E. Grey; J. Mardiak; L. Jurga; A. Sabo; J. Sufliarsky; L. Sevcikova; D. Sorkovska; D. West; J. Trupl; J. Novotny; F. Mateicka
Abstract Forty-five cases of fungaemia due non-albicans Candida spp. (NAC) in a single National Cancer Institution within 10 years were analysed for aetiology, risk factors and outcome. There had been 12 cases of fungaemia that were due to C. krusei, 14 due to C. parapsilosis, 7 due to C. (T.)glabrata, 6 to C. tropicalis, 2 to C. guillermondii, 2 to C. lusitaniae, 1 to C. stellatoidea, and 1 to C. rugosa. Comparison of 45 NAC fungaemia with 75 episodes of C. albicans fungaemia revealed differences only in two risk factors: previous empiric therapy with amphotericin B (16.0 vs 2.2%, P<0.01) appeared more frequently in cases of C. albicans fungaemia, and prior prophylaxis with fluconazole (8.9 vs 0%, P<0.02) was conversely more frequently observed with NAC. The incidence of other risk factors, such as underlying disease, chemotherapy, antibiotic prophylaxis or therapy, treatment with corticosteroids, catheter insertion, mucositis, cytotoxic chemotherapy, and neutropenia, was similar in both groups. There was no difference either in attributable or in overall mortality between NAC and C. albicans fungaemia in our cancer patients.
Journal of Chemotherapy | 2003
V. Krcmery; Maria Gogova; Adriana Ondrusova; E. Buckova; Andrea Doczeova; M. Mrazova; V. Hricak; V. Fischer; P. Marks
Abstract The authors studied the etiology, outcome and risk factors of 339 cases of infective endocarditis (IE) in Slovakia over the last 10 years. Aortic valve was infected in 59.9%, mitral in 38.1% and tricuspidal/pulmonary in 5.0% of cases. The majority of IE were caused by staphylococci (29.2%), 15.0% were due to viridans streptococci, 7.4% due to Enterococcus faecalis, 3.9% due to the HACEK group (Haemophilus spp., Actinobacillus spp., Corynebacterium spp., Eikenella spp., Kingella spp.) and 39.2% were culture negative. The following risk factors were the most frequently identified: rheumatic fever in 24.2%, dental surgery in 13.3%, previous cardiosurgery in 7.1% and neoplasia in 7.1%. All patients were treated with antimicrobials and 42.5% of patients also with surgery (valvular prosthesis replacement): 61 (18.0%) died, and 278 (82.0%) survived at day 60 after the diagnosis of endocarditis was made. Univariate analysis did not show significant differences in most of the recorded risk factors between patients who died and those who survived: apart from staphylococcal etiology (44.3% vs. 26.6%, P <0.01), persistent bacteremia (with three or more positive blood cultures 24.6% vs. 9.7% P <0.002) which were significantly associated with higher attributable mortality, as was absence of surgery (55.7% vs. 6.1% P < 0.001), whereas antibiotic therapy in combination with surgery significantly predicted better outcome (P <0.001). We compared risk factors, etiology, therapeutic strategies and outcome of IE in two periods: from 1991-1997 (180 cases) and from 1998-2001 (159 cases). Rheumatic fever was less commonly observed in second period (1998-2001) P <0.01 since its prevalence in Slovakia is rapidly decreasing. Dental surgery was less frequent as well (20.5% vs. 5.0% P <0.001). There was a significant shift in etiology within the second study period: negative-culture endocarditis (despite better bacteriological techniques) (P <0.001) was more frequently observed in the 1st period and represented 53.3% of all cases in 1998-2001 in comparison to 26.7% in 1991-1997. Enterococci (P <0.0002) were also more frequent in the 2nd period. Persistent bacteremia (3 or more positive blood cultures 20.5% vs. 3.1%, P <0.001 was less commonly observed within the 2nd period (1998-2001) in comparison to 1991-1997. More patients in the second period (1998-2001) had complications of IE (P<0.001) than in the 1st period. However mortality was lower (22.2% vs. 13.2%, P <0.044) because of more surgical intervention in the 2nd period (52.8% vs. 33.3%, P <0.001).
Scandinavian Journal of Infectious Diseases | 1997
K. Kralovicová; S. Spanik; E. Oravcova; M. Mrazova; E. Morova; V. Gulikova; E. Kukuckova; P. Koren; P. Pichna; J. Nogova; A. Kunova; J. Trupl; V. Krcmery
26 patients with fungemia and cancer treated with chemotherapy (group A) were compared to 25 patients with fungemia and cancer treated with surgery (group B), to assess differences in etiology, risk factors and outcome. Candida albicans was responsible for 42% of fungemias in group A, and for 92% of fungemias in group B (p < 0.005). Breakthrough fungemia occurring during antifungal prophylaxis appeared in 46.6% of group A vs 12% of group B (p < 0.02). There was significant difference in outcome between the groups: 20% of patients after surgery vs 7.7% of those after chemotherapy died from fungemia (p < 0.04). Most common risk factors recorded in both groups were catheter insertion and previous therapy with broad spectrum antibiotics.
Supportive Care in Cancer | 1997
S. Spanik; E. Kukuckova; P. Pichna; S. Grausova; I. Krupova; V. Rusnakova; K. Kralovicova; Adriana Krchnakova; M. Mrazova; J. Lacka; P. Koren; K. Stopkova; J. Nogova; A. Demitrovicova; L. Helpianska; V. Krcmery
Abstract Relationships between aetiology, various risk factors (such as neutropenia, catheter insertion, endoscopy, therapy with corticosteroids, therapeutic use of antimicrobials, antibiotic prophylaxis, source of infection), symptomatology and outcome were studied in 553 monomicrobial bacteraemic episodes in cancer patients observed within 7 years at the National Cancer Institute of the Slovak Republic. The ratio of gram-positive to gram-negative bacteraemia was 1:1 (43.5% vs 43.8%), and yeasts caused 7.2% of monomicrobial episodes. The highest mortality was associated with Pseudomonas aeruginosa (19.2%), non-albicans Candida yeasts (25%) and Bacteroides fragilis (22.6%). Independent risk factors for particular pathogens were investigated by a computerized logistic regression model. The only independent risk factor for staphylococcal and enterococcal bacteraemia was vascular catheter insertion (OR=1.95 and 2.05, CI=95%, P=0.035 and 0.044, respectively). However, there were no independent specific risk significant factors for viridans streptococcal bacteraemia and bacteraemia due to Enterobacteriaceae or Ps. aeruginosa. Neutropenia was found to be an independent predictor for development of Acinetobacter spp. bacteraemia (OR=3.84, CI=95%, P=0.044). Prior therapy with third-generation cephalosporines was a predictive, independent risk factor for the development of fungaemia (OR=1.99, CI=95%, P=0.028) but not of enterococcal bacteraemia. We also did not observe any association between prior therapy with imipenem and Stenotrophomonas maltophilia bacteraemias. Multivariate analysis confirmed that fungaemia may be independently associated with higher mortality than bacteraemia caused by Enterobacteriaceae and staphylococci. However, the mortality of fungaemia was statistically no different from that of Ps. aeruginosa, Stenotrophomonas spp. and viridans streptococci bacteraemias.
International Journal of Infectious Diseases | 2002
V. Krcmery; S. Spanik; M. Mrazova; J. Trupl; S. Grausova; E. Grey; E. Kukuckova; Margita Sulcova; Iveta Krupova; P. Koren
OBJECTIVES The aims of this study were to evaluate risk factors, clinical presentation, outcome and antimicrobial susceptibility in patients with Escherichia coli bacteremia occurring over seven years in a single cancer hospital. METHODS Sixty five episodes of bacteremia from E. coli appearing over seven years from 12,301 admissions in a single cancer institution were retrospectively analyzed. RESULTS The proportion of bacteremia caused by E. coli among Gram-negative bacteremia was 20.8% (the second most common organism after Pseudomonas aeruginosa), and infection-associated mortality was 17%. The incidence in 1989-1995 varied from 14.3 to 24.7%. The most common risk factors were: solid tumors as the underlying disease (70.7%); central venous catheter insertion (32.3%); prior surgery (46.2%), and prior chemotherapy within 48 h (44.4%). Neutropenia and urinary catheters did not place patients at high risk in any of the subgroups. When we compared the two subgroups of 61 cases of bacteremia - monomicrobial and polymicrobial (when E. coli was isolated from blood culture with another microorganism) - we found that acute leukemia and breakthrough (recurrence while receiving antibiotics) bacteremia were more frequently associated with polymicrobial E. coli bacteremia. There was also a difference in infection-associated mortality: monomicrobial bacteremia due to E. coli only had a significantly lower mortality in comparison with polymicrobial E. coli bacteremia (8.9 vs 35.0%, respectively; P<0.03). CONCLUSION The susceptibility of 115 E. coli strains isolated from 65 episodes of bacteremia was stable. Only two episodes caused by quinolone-resistant strains occurred, both in 1995, after six years of using ofloxacin for prophylaxis in neutropenic patients in our hospital. We found that 85.2-91.3% of all strains were susceptible to aminoglycosides, 97.8% to quinolones, and 90-100% to third generation cephalosporins and imipenems. The patients most commonly infected had solid tumors and the mortality was only 17%.
Journal of Chemotherapy | 2005
J. Koprnova; P. Beno; Jarmila Korcova; M. Mrazova; E. Grey; A. Liskova; A. Harnicarova; M. Karvaj; S. Koval; V. Zak; M. Danaj; A. Streharova; E. Mitterpachova; J. Miklosko; Adriana Ondrusova; J. Riedl; E. Kaiserova; V. Prokopova; M. Hornova; J. Payer; B. Rudinsky; L. Pevalova; M. Bencelova; J. Hanzen; L. Mačeková; J. Csölleyova; V. Krcmery
Abstract Risk factors, mortality and antimicrobial susceptibility of Pseudomonas aeruginosa bacteremias isolated from 148 patients from all University Hospitals in Slovakia were analyzed. Only 1.2% of 169 strains of P. aeruginosa were resistant to meropenem, 4.1% to piperacillin/tazobactam, 7.7% to ceftazidime as well as cefepime and 12% to amikacin. More than 30% of P. aeruginosa were resistant to ciprofloxacin. Our analysis of risk factors for antimicrobial resistance to the particular antimicrobials, indicated no difference in risk factors and outcome in cases infected with P. aeruginosa bacteremias resistant to amikacin, piperacillin/tazobactam or ceftazidime in comparison to episodes caused by P. aeruginosa due to susceptible isolates. When comparing risk factors for P. aeruginosa bacteremia in children vs. adults, cancer vs. non-cancer patients, several differences in risk factors were observed. Neither antimicrobial resistance to amikacin, ceftazidime or piperacillin/tazobactam, nor appropriateness of therapy according to two separate analyses were associated with better outcome.
Journal of Antimicrobial Chemotherapy | 2001
V. Krcmery; M. Huttova; F. Mateicka; Ladislav Laho; L. Jurga; Adriana Ondrusova; Zuzana Tarekova; K. Kralinsky; J. Hanzen; Anna Liskova; M. Mrazova; A. Sabo; Maria Pisarcikova; G. Kovacicova; Darina Chovancova; Zuzana Szovenyiova
Clinical Social Work and Health Intervention | 2017
Andrea Shahum; A. Kalavska; M. Chabadova; Erich Kalavsky; J. Benca; M. Mrazova; J. Polonova; Pavol Tomanek; M. Obtulovic; S. Dobrodenkova; V. Sladeckova; N. Bujdova; T. Hrindova; Gertruda Mikolasova; R. Sladicekova; P. Horak; Z. Dudova; J. Adamcova; S. Spanik; M. Belovicova; Ivan Bartosovic; S. Laca; T. Bak; A. Gallova; Michael Olah; V. Krcmery
Clinical Social Work and Health Intervention | 2017
Gertruda Mikolasova; Igor Kmit; V. Krcmery; Katerina Prochazkova; Anna Liskova; M. Mrazova; M. Karvaj; Ladislav Bucko; J. Benca; Maria Hardy; Libusa Radkova; Michael Olah; Jana Marsova; Martina Pavlova; Robert Kovac; Jana Vallova; Viera Hulkova; Selvaraj Subramanina; Daniel West
Clinical Social Work and Health Intervention | 2017
Dagmar Kalatova; Kaled Ibrahim; Anna Liskova; V. Krcmery; Gertruda Mikolasova; Gyorgy Herdics; J. Suvada; Catherine Zoller; Martin Bibza; Ladislav Bucko; M. Mrazova; Juraj Ondrejka; Timea Lassakova; Peri Hajj Ali; Peter Juris; Jan Bydzovsky; Monika Jankechova